Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) has launched a new podcast called 'Gut Matters: Discoveries and Innovations' for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is co-hosted by Johannah Ruddy, M.Ed., Ardelyx's director of patient advocacy, and Dr. Andrea Shin, a practicing gastroenterologist.

The monthly podcast will feature discussions with patients, caregivers, advocacy leaders, healthcare providers, and gastroenterology experts about the impact of IBS-C. It aims to provide education, hope, and valuable insights for those affected by the condition. The hosts hope to create a safe space where people with IBS-C can find fact-based information and hear relatable stories, empowering patients and their support networks.

The first episode is already available, and interested individuals can subscribe to the podcast on various platforms.

Positive

• Launch of a new podcast targeting the IBS-C patient community, potentially expanding Ardelyx's reach and brand awareness
• Collaboration with healthcare professionals and experts in the field, which may enhance the company's credibility

Negative

• None.

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx’s director, patient advocacy, Johannah Ruddy, M.Ed. and practicing gastroenterologist, Andrea Shin, MD. The first episode is out now. Each month, the hosts will be joined by patients, caregivers, advocacy leaders, healthcare providers and other gastroenterology experts to discuss the impact of IBS-C and provide education and hope for those affected.

“People living with IBS-C often feel lonely and stigmatized. We wanted to create a safe space where people with this condition can find fact-based information, hear stories that likely sound like their own, and gain valuable insights that will provide them with hope as well as the tools to better manage their condition,” said Andrea Shin, MD and podcast co-host. “I am really proud to be a part of the Gut Matters: Discoveries and Innovations podcast. Our hope is to empower patients, family members and caregivers by showing them that they are part of a large community.”

Individuals can subscribe to the podcast and keep up on the latest episodes here, or wherever they get their podcasts.

About Irritable Bowel Syndrome with Constipation (IBS-C)
Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

What is the name of Ardelyx's new podcast for IBS-C patients?

Ardelyx's new podcast for IBS-C patients is called 'Gut Matters: Discoveries and Innovations'.

Who are the hosts of Ardelyx's (ARDX) new IBS-C podcast?

The podcast is co-hosted by Johannah Ruddy, M.Ed., Ardelyx's director of patient advocacy, and Dr. Andrea Shin, a practicing gastroenterologist.

How often will new episodes of Ardelyx's (ARDX) IBS-C podcast be released?

New episodes of the 'Gut Matters: Discoveries and Innovations' podcast will be released monthly.

What is the main goal of Ardelyx's (ARDX) new podcast for IBS-C patients?

The main goal of the podcast is to provide education, hope, and valuable insights for those affected by IBS-C, creating a safe space for patients to find fact-based information and hear relatable stories.